# To Evaluate the Pharmacokinetics and Safety of TQD3606 for Injection in Subjects With Renal Insufficiency

> **NCT06672276** · PHASE1 · COMPLETED · sponsor: **Chia Tai Tianqing Pharmaceutical Group Co., Ltd.** · enrollment: 32 (actual)

## Conditions studied

- Resistant to Gram-positive, Gram-negative and Anaerobic Bacteria

## Interventions

- **DRUG:** TQD3606

## Key facts

- **NCT ID:** NCT06672276
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-11-20
- **Primary completion:** 2025-05-06
- **Final completion:** 2025-05-06
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2026-01-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06672276

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06672276, "To Evaluate the Pharmacokinetics and Safety of TQD3606 for Injection in Subjects With Renal Insufficiency". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06672276. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*